With its stable socio-political environment, strong intellectual property laws, and established links to the Asia-Pacific region, Australia enjoys some significant global and regional advantages. Despite its relatively small population, a Pharmaceuticals Industry Strategy Group report shows Australia has a healthy number of pharmaceutical companies, including more than 40 originator companies (predominantly subsidiaries of multinational companies), around 10 generic companies, 470 small-scale core biotechnology companies, and more than 20 world-class medical…
Current Clinical Trial Activity in Australia
An Industry Perspective on Australia’s Reimbursement Program
Graham Edwards. Managing Director, Ogilvy Healthworld Sydney, a part Ogilvy CommonHealth Worldwide, the health behavior experts of Ogilvy & Mather (ogilvy.com), representing one of the largest assemblies of creative talent in the world of healthcare communications with 66 offices across 36 countries. For more information, visit ogilvychww.com.
Terry Hisey. Vice Chairman and U.S. Life Sciences Leader, Deloitte, part of a global network of member firms in more than 150 countries that provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. For more information, visit, deloitte.com.
Ash Kuchel. President Asia Pacific, Publicis Healthcare Communications Group, a healthcare communications network and a division of Publicis Groupe S.A. For more information, visit publicishealthcare.com.
Brendan Shaw, Ph.D. Chief Executive, Medicines Australia, which represents the discovery-driven pharmaceutical industry in Australia. For more information, visit medicinesaustralia.com.au.
Nick Ward. Principal Consultant, Pharma to Market, an Australia-based consulting company providing global regulatory support services and outsourcing solutions to the pharmaceutical industry. For more information, visit pharmatomarket.com.